Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
prolonging spray.
Popular Articles

Acupuncture May Be Beneficial In Relieving Indigestion During Pregnancy
A small study published in Acupuncture Medicine reports that acupuncture may be beneficial in easing symptoms of indigestion which are very frequent in pregnant women. The hormonal changes in the body during pregnancy cause heartburn, stomach pain and discomfort, reflux, belching and bloating. Between 45 to 80 percent of women are reported to experience those symptoms.
generic viagra
Opinion Pieces Examine Recent Public Opinion Polls On Abortion
Two newspapers recently published opinion pieces on abortion-related public opinion polls. Summaries appear below.~ Steven Kull, Baltimore Sun: Although "many Americans feel morally conflicted about" abortion, it is a "common error to believe that the American electorate is deeply divided about how the government should deal with" the procedure, Kull -- director of WorldPublicOpinion.org and the Program on International Policy Attitudes at the University of Maryland -- writes in a Sun opinion piece. He adds that "there is substantial consensus that the government should not criminalize abortion." According to Kull, a new CNN poll found that 68% of respondents believe Roe v. Wade should not be overturned, and a recent WorldPublicOpinion.org poll found that when asked, "Do you think the government should be involved in trying to discourage abortion or do you think the government should leave these matters to the individual," 69% said that the matter should be left to the individual. Kull adds that "of the 29% who said that the government should be involved in trying to discourage abortions, a remarkably low 8% favored using criminal enforcement methods." According to Kull, other polls have found if "given a middle option -- somewhere between strict prohibition and government permission -- a significant number will choose it." Kull writes that "once the moral question is differentiated from the question of how the government should act, it does appear that there is substantial consensus that abortion should not be criminalized." He concludes, "Once the option of criminal enforcement is taken off the table, constructive options are more likely to emerge and can be an effective focus for the energies freed up from the incessant debates about abortion" (Kull, Baltimore Sun, 5/22).~ Cheryl Wetzstein, Washington Times: "It"s rather ironic that as the most pro-choice government in U.S. history settles into its seats," a Gallup poll "finds that most Americans are pro-life," columnist Wetzstein writes in a Times opinion piece. She adds, "Some observers have tried to pooh-pooh this result, but it doesn"t surprise me for two reasons." Wetzstein writes that her "experience with youth, both personally and professionally, is that they often recoil at abortion," adding, "So I find a pro-life trend in youth to be quite plausible." She continues, "Second, I think some aging baby boomers are changing their views," adding, "People generally become more conservative and self-reflective with age. Legacies matter. Hindsight is 20/20. Regrets appear." Wetzstein concludes, "My suspicion is that in more than a few cases, baby boomers who were willing to have abortions are not at ease with the idea of losing their grandchildren," adding, "It may be that in the autumn of life, being "pro-life" has a whole new meaning" (Wetzstein, Washington Times, 5/26).
Zubni implantati
News of the day
÷£100 Million Social Marketing Campaign To Encourage Responsible Drinking Announced, UK
Following Gordon Brown"s meeting at Downing Street with Britain"s top drinks industry executives he called for them to harness their considerable marketing powers to drive for change in social norm and cultural attitudes towards alcohol in the UK. This has resulted in Project "N" - a collaboration of the not inconsiderable res of top companies throughout the UK.
Mental Health

Novexel To Present Four Posters At The 19th European Congress Of Clinical Microbiology And Infectious Diseases In Helsinki

Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces that its two most advanced pipeline products NXL104 and NXL103 are the subject of four posters at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). The ECCMID conference is taking place in Helsinki between 16th and 19th May 2009. NXL104, Novexel"s broad spectrum class A and C beta-lactamase inhibitor, is the subject of one poster. Novexel is currently conducting two Phase II clinical trials in patients with complicated urinary tract infections and complicated intra-abdominal infections with NXL104 in combination with ceftazidime. The poster provides in vitro data showing that a ceftazidime/NXL104 combination is rapidly bactericidal against a range of beta-lactamase-producing strains of Enterobacteriaceae, including E. coli, and Klebsiella. Data presented also showed that one of the most important factors affecting the pharmacodynamics of the combination is maintaining a critical concentration of the inhibitor (NXL104) to suppress beta-lactamase activity. (Poster P 1463). NXL103, a novel oral streptogramin antibiotic, is the subject of three posters at the ECCMID conference. Novexel has recently completed a successful Phase II study with NXL103 in patients with community acquired pneumonia. The first of the three posters provides in vitro data showing that NXL103 was active against methicillin resistant Staphylococcus aureus (MRSA) and organisms responsible for lower respiratory tract infections, including Streptococcus pneumoniae and Haemophilus influenzae , (Poster P 1393). The second poster contains in vivo data demonstrating that, following oral administration, NXL103 was able to kill intracellular drug-resistant and non-drug-resistant strains of Staphylococcus aureus in infected macrophages, (Poster P 1025). The final poster shows that NXL103 was active in vitro against both community-acquired and hospital-acquired strains of MRSA. The poster also showed that NXL103 was subject to a low spontaneous frequency of resistance (Poster P 1102). It is Novexel"s intention to seek partners for both the NXL104/ceftazidime combination and NXL103 in certain geographies. About Novexel Novexel is a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance. The ever increasing resistance to marketed antibiotics has led to a clear need for novel drugs that are active against multi-drug resistant bacteria. Novexel"s products are targeting the global hospital antibiotic market, which was worth an estimated US$17bn in 2008.[1] Novexel currently has two novel antibacterials in Phase II clinical development. These are the injectable beta-lactamase inhibitor, NXL104, which is being developed in combination with the cephalosporin antibiotic ceftazidime for serious Gram negative infections, and the oral streptogramin antibiotic, NXL103, for the treatment of Gram positive infections, with a focus on treatment in the hospital setting and intravenous (IV) to oral switch. Novexel has three further programmes in preclinical development, NXL105, a novel anti-Pseudomonal antibiotic, NXL201, a novel echinocandin antifungal agent, and NXL104 in combination with ceftaroline. This latter product is being developed by Novexel"s partner, Forest Laboratories (NYSE: FRX), solely for North American markets. Novexel was created in December 2004 as an independent spin-out of the sanofi-aventis (Euronext Paris: SAN, NYSE: SNY) anti-infectives unit. Novexel has a team of 50 employees with significant experience in anti-infective research and development, who are located in Paris, France and Philadelphia, USA. [1] IMS Health, MIDAS, 2006-2008 Novexel


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009